Literature DB >> 8119701

Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group.

R W Ammann1, N Ilitsch, B Marincek, A U Freiburghaus.   

Abstract

The efficacy of long-term chemotherapy in nonresectable alveolar echinococcosis is debated, particularly because of the difficulty in defining therapeutic success. In this study the effect of chemotherapy on the parasitic mass was evaluated in a series of 37 patients. The patients had larval lesions documented by serial computed tomography studies at least 1.5 yr after chemotherapy (mean = 6.4 yr, range = 1.5 to 10.7 yr). The therapeutic regimen consisted of mebendazole (n = 34) or albendazole (n = 3) as previously described. The maximal areas of the parasitic lesions were assessed morphometrically by means of digital image analysis, utilizing the point-integration method, before and after chemotherapy. Marked regression of larval tissue occurred in 18 patients (group A; 48.6%), stationary lesions were noted in 13 patients (group C; 35.1%) and progression was found in 6 patients (group B; 16.2%). The three groups did not differ significantly with regard to age, plasma drug levels, duration of chemotherapy or initial size and composition of lesions (e.g., cystic cavities, degree of calcification). Despite morphologically successful chemotherapy in moist patients (e.g., 84%; groups A and C), late cholestatic complications after 1.5 to 11 yr of chemotherapy occurred in 10 patients (group A, n = 7; group C, n = 3; 4 of them died) and esophageal variceal bleeding occurred in 3 patients (relieved by sclerotherapy). These late complications were probably mainly due to posttherapy fibrosis of hilar structures. In conclusion, our data support the efficacy of chemotherapy. However, chemotherapy is not curative, and severe late complications were observed in patients with hilar (fibrotic) involvement.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8119701     DOI: 10.1002/hep.1840190328

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

1.  Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes.

Authors:  K Ingold; P Bigler; W Thormann; T Cavaliero; B Gottstein; A Hemphill
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae.

Authors:  Stefan Reuter; Burkhard Manfras; Marion Merkle; Georg Härter; Peter Kern
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes.

Authors:  H Jura; A Bader; M Frosch
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Major carbohydrate antigen of Echinococcus multilocularis induces an immunoglobulin G response independent of alphabeta+ CD4+ T cells.

Authors:  W J Dai; A Hemphill; A Waldvogel; K Ingold; P Deplazes; H Mossmann; B Gottstein
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

6.  Echinococcus multilocularis alkaline phosphatase as a marker for metacestode damage induced by in vitro drug treatment with albendazole sulfoxide and albendazole sulfone.

Authors:  M Stettler; M Siles-Lucas; E Sarciron; P Lawton; B Gottstein; A Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.

Authors:  Nilambra Dogra; Tapas Mukhopadhyay
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

8.  Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.

Authors:  Stefan Reuter; Andreas Buck; Olaf Grebe; Karin Nüssle-Kügele; Peter Kern; Burkhard J Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Effect of amphotericin B on larval growth of Echinococcus multilocularis.

Authors:  Stefan Reuter; Marion Merkle; Klaus Brehm; Peter Kern; Burkhard Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  European echinococcosis registry: human alveolar echinococcosis, Europe, 1982-2000.

Authors:  Petra Kern; Karine Bardonnet; Elisabeth Renner; Herbert Auer; Zbigniew Pawlowski; Rudolf W Ammann; Dominique A Vuitton; Peter Kern
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.